Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

NEWS FEEDS

Comparative Effectiveness Research: Do Employers Care? What Will They Do? What About Productivity?

This article discusses a survey of employers, conducted by the Benfield Group and supported by the National Pharmaceutical Council, that found that one of the benefits employers are looking for from comparative effectiveness research (CER) is more information about which treatments help with productivity. While data is beginning to emerge regarding the links between good health, productivity and employee wellness programs, this survey shows that most companies (or the benefit consultants they work with) do not have access to the information or any ability to use it in their decision-making.

Specifically, while fewer than one-third of employers or their vendors currently use information about absence, disability and return to work assessing the impact of alternative treatments, 70 percent indicate that such information would be “Important” or “Very Important” within CER. And, while fewer than 25% now use information about the impact of alternative treatments on work productivity in making decisions, over 60% rate this information as “Important” or “Very Important” in CER.

In a more direct analysis of the benefit of CER to employers, respondents were asked how they would handle two specific scenarios related to treatments for low back pain and diabetes. According to the findings, employers are generally more likely to take action based on CER evidence regarding diabetes. The reasons given include the “perceived higher total costs” of treating diabetes and a belief that it would be easier to make changes to address diabetes based on “already generally accepted guidelines for treatment.”

In addition to productivity related information, additional survey findings of note include clear messages about what other types of information employers want: “clinical outcomes of alternative treatments; information comparing utilization and cost of treatments; information about which treatments work best for specific population, and; comparative safety of alternative treatments.”

Although a subscription to the JOEM is required to read this article, the full study, survey instrument and video are available on NPC's website.

Blog Post

CER Tweets of the Week: New UMB Center of Excellence In CER, UIC College of Pharmacy Master’s in CER, PCORI in Lancet (January 19-23)

Comparative effectiveness research (CER) stakeholders tweeted about new educational opportunities regarding CER. They shared an announcement about a...
Blog Post

CER Tweets of the Week: The Challenges of Gray-Zone Medicine, PCORI in the Congress Blog (January 12-16)

This week, comparative effectiveness research (CER) stakeholders tweeted multiple articles regarding CER and various challenges they face. They...
Blog Post

CER Tweets of the Week: AcademyHealth Compares International CER, Resource Library on CER (January 5-9)

This week, comparative effectiveness research (CER) stakeholders tweeted about @AcademyHealth’s new paper comparing international efforts to boost...
Commentary and Testimony Page

Chain Drug Review – Commentary: “Health Care Outlook for 2015”

This commentary was originally published in the January 5, 2015 issue of Chain Drug Review.By: Dan Leonard, President, National Pharmaceutical...
Press Release

National Pharmaceutical Council, Discern Health Examine Accountable Care Measures for Specialty Care and Innovative Treatment

Washington, DC (October 28, 2014)— Measuring the quality and cost of health care is an integral part of accountable care, but new research from the...
Press Release

NPC Study Outlines When & How Health Decision-Makers Should Consider Individual Patient Differences

Washington, DC (July 29, 2014)—New research led by the National Pharmaceutical Council (NPC) can assist health care stakeholders to understand when...
Press Release

Specialty Medications: Shifting the Focus From “How Much” We Spend to “How Well” We Spend

Washington, DC, June 9, 2014—As health care decision-makers grapple with how to ensure access to specialty medications, the University of Michigan...
Press Release

NPC Annual Stakeholder Survey: Comparative Effectiveness Research Is Important, But Impact on Health Care Decision-Making Is Still on the Horizon

(Washington, DC, May 19, 2014)—A new survey of health care stakeholders reveals continued optimism for the use of comparative effectiveness research...
Commentary and Testimony Page

Chain Drug Review – Commentary: “Health Care Outlook for 2015”

This commentary was originally published in the January 5, 2015 issue of Chain Drug Review.By: Dan Leonard, President, National Pharmaceutical...
Commentary and Testimony Page

NPC Comments on PCORI Proposal for Peer Review of Primary Research and Public Release of Research Findings

November 7, 2014Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036Dear Dr....
Commentary and Testimony Page

The State of CER and the Environment for Health Care Decision Making

This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...
Commentary and Testimony Page

Keeping Our Eye on the CER Ball

Until the cherry blossoms begin to bloom later next month, most of the water cooler conversations in Washington will focus on the federal budget....
YouTube Videos

Why are quality measures important? We asked health care thought leaders to tell us why.

Quality measurement, tied to financial incentives, is one of many approaches accountable care programs are using to promote system-wide improvement....
YouTube Videos

Access to Specialty Medications & Value-Based Insurance Design

Specialty medications have been making health care headlines because of their effectiveness and higher costs. How can we ensure that patients will...
YouTube Videos

Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice

National Pharmaceutical Council Chief Science Officer Robert W. Dubois, MD, PhD, discusses a peer-reviewed study suggesting that changes are needed...
YouTube Videos

Shifting the Focus From "How Much" to "How Well" We Spend Our Health Care Dollars

A. Mark Fendrick, MD, director of the Center for Value-Based Insurance design at the University of Michigan, highlights the key findings from a...
Blog Post

CER Tweets of the Week: New UMB Center of Excellence In CER, UIC College of Pharmacy Master’s in CER, PCORI in Lancet (January 19-23)

Comparative effectiveness research (CER) stakeholders tweeted about new educational opportunities regarding CER. They shared an announcement about a...
Blog Post

CER Tweets of the Week: The Challenges of Gray-Zone Medicine, PCORI in the Congress Blog (January 12-16)

This week, comparative effectiveness research (CER) stakeholders tweeted multiple articles regarding CER and various challenges they face. They...
Blog Post

CER Tweets of the Week: AcademyHealth Compares International CER, Resource Library on CER (January 5-9)

This week, comparative effectiveness research (CER) stakeholders tweeted about @AcademyHealth’s new paper comparing international efforts to boost...
Blog Post

CER Tweets of the Week: Clinical Uncertainty in Surgery and EBM & Patient-Centered Medicine and EBM (December 29 – January 2)

This week, articles about evidence-based medicine (EBM) attracted the attention of comparative effectiveness research (CER) stakeholders on Twitter....

Research

Accountable Care Measures for High-Cost Specialty Care and Innovative Treatment

This research sheds light on gaps in quality measurement and missed opportunities to promote...

Consumer-Directed Health Plans: Pharmacy Benefits & "Better Practices"

On behalf of the National Pharmaceutical Council, Th

  •  
  • 1 of 24
  • >

Commentary & Testimony